213 related articles for article (PubMed ID: 32005809)
1. Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist.
Parisi G; Saco JD; Salazar FB; Tsoi J; Krystofinski P; Puig-Saus C; Zhang R; Zhou J; Cheung-Lau GC; Garcia AJ; Grasso CS; Tavaré R; Hu-Lieskovan S; Mackay S; Zalevsky J; Bernatchez C; Diab A; Wu AM; Comin-Anduix B; Charych D; Ribas A
Nat Commun; 2020 Jan; 11(1):660. PubMed ID: 32005809
[TBL] [Abstract][Full Text] [Related]
2. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
[TBL] [Abstract][Full Text] [Related]
3. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
[TBL] [Abstract][Full Text] [Related]
4. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK
Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745
[TBL] [Abstract][Full Text] [Related]
5. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy.
Miyazaki T; Maiti M; Hennessy M; Chang T; Kuo P; Addepalli M; Obalapur P; Sheibani S; Wilczek J; Pena R; Quach P; Cetz J; Moffett A; Tang Y; Kirk P; Huang J; Sheng D; Zhang P; Rubas W; Madakamutil L; Kivimäe S; Zalevsky J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34001523
[TBL] [Abstract][Full Text] [Related]
6. In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes.
Zheng Y; Stephan MT; Gai SA; Abraham W; Shearer A; Irvine DJ
J Control Release; 2013 Dec; 172(2):426-35. PubMed ID: 23770010
[TBL] [Abstract][Full Text] [Related]
7. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
8. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
9. NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells.
Robinson TO; Hegde SM; Chang A; Gangadharan A; Rivas S; Madakamutil L; Zalevsky J; Miyazaki T; Schluns KS
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375310
[TBL] [Abstract][Full Text] [Related]
10. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Bentebibel SE; Hurwitz ME; Bernatchez C; Haymaker C; Hudgens CW; Kluger HM; Tetzlaff MT; Tagliaferri MA; Zalevsky J; Hoch U; Fanton C; Aung S; Hwu P; Curti BD; Tannir NM; Sznol M; Diab A
Cancer Discov; 2019 Jun; 9(6):711-721. PubMed ID: 30988166
[TBL] [Abstract][Full Text] [Related]
11. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract][Full Text] [Related]
12. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
[TBL] [Abstract][Full Text] [Related]
13. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
15. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
[TBL] [Abstract][Full Text] [Related]
16. Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells.
Lee PH; Yamamoto TN; Gurusamy D; Sukumar M; Yu Z; Hu-Li J; Kawabe T; Gangaplara A; Kishton RJ; Henning AN; Vodnala SK; Germain RN; Paul WE; Restifo NP
J Exp Med; 2019 Nov; 216(11):2619-2634. PubMed ID: 31405895
[TBL] [Abstract][Full Text] [Related]
17. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
18. Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells.
Xie YQ; Arik H; Wei L; Zheng Y; Suh H; Irvine DJ; Tang L
Biomater Sci; 2019 Mar; 7(4):1345-1357. PubMed ID: 30698174
[TBL] [Abstract][Full Text] [Related]
19. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
[TBL] [Abstract][Full Text] [Related]
20. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
